New cream may soothe painful rash from cancer treatment
NCT ID NCT06399029
First seen Nov 19, 2025 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This study tests whether a cream containing ruxolitinib can reduce the skin rash that often occurs during anti-PD1 cancer therapy. About 22 adults with this rash will apply the cream for 12 weeks. The goal is to see if the rash improves by at least 90%.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXANTHEMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University hospital Zürich, Department Dermatology
Zurich, 8091, Switzerland
Conditions
Explore the condition pages connected to this study.